P. Tomasini , Y. Wang , S-H. Lee , J. Cui , E. Felip , A. Spira , Y. Li , L. Wu , S. Michels , E. Ichihara , J. Neal , L. Demirdjian , C.S. Meyer , Y. Zhang , H. Kanakamedala , A. Louder , L. Trani , I. Leconte , M. Baig , B.C. Cho
{"title":"59P:在非典型EGFR突变晚期NSCLC患者的匹配现实世界队列中,评估amivantamab + lazertinib在CHRYSALIS-2与EGFR TKI单药治疗中的有效性","authors":"P. Tomasini , Y. Wang , S-H. Lee , J. Cui , E. Felip , A. Spira , Y. Li , L. Wu , S. Michels , E. Ichihara , J. Neal , L. Demirdjian , C.S. Meyer , Y. Zhang , H. Kanakamedala , A. Louder , L. Trani , I. Leconte , M. Baig , B.C. Cho","doi":"10.1016/S1556-0864(25)00254-0","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":"20 3","pages":"Pages S47-S48"},"PeriodicalIF":21.0000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"59P: Evaluating the effectiveness of amivantamab plus lazertinib in CHRYSALIS-2 vs EGFR TKI monotherapy in a matched real-world cohort of participants with atypical EGFR-mutated advanced NSCLC\",\"authors\":\"P. Tomasini , Y. Wang , S-H. Lee , J. Cui , E. Felip , A. Spira , Y. Li , L. Wu , S. Michels , E. Ichihara , J. Neal , L. Demirdjian , C.S. Meyer , Y. Zhang , H. Kanakamedala , A. Louder , L. Trani , I. Leconte , M. Baig , B.C. Cho\",\"doi\":\"10.1016/S1556-0864(25)00254-0\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":17515,\"journal\":{\"name\":\"Journal of Thoracic Oncology\",\"volume\":\"20 3\",\"pages\":\"Pages S47-S48\"},\"PeriodicalIF\":21.0000,\"publicationDate\":\"2025-03-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Thoracic Oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1556086425002540\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Thoracic Oncology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1556086425002540","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
59P: Evaluating the effectiveness of amivantamab plus lazertinib in CHRYSALIS-2 vs EGFR TKI monotherapy in a matched real-world cohort of participants with atypical EGFR-mutated advanced NSCLC
期刊介绍:
Journal of Thoracic Oncology (JTO), the official journal of the International Association for the Study of Lung Cancer,is the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis, and treatment of all thoracic malignancies.The readship includes epidemiologists, medical oncologists, radiation oncologists, thoracic surgeons, pulmonologists, radiologists, pathologists, nuclear medicine physicians, and research scientists with a special interest in thoracic oncology.